Report error Found 542 Enz. Inhib. hit(s) with Target = 'Programmed cell death protein 1'
Affinity DataKd: 3.39E+3nMAssay Description:Binding affinity to human PD1 (34 to 150 residues) expressed in Escherichia coli BL21 (DE3) measured for 120 secs by SPR analysisMore data for this Ligand-Target Pair
Affinity DataKd: 3.14E+3nMAssay Description:Binding affinity to human PD1 (34 to 150 residues) expressed in Escherichia coli BL21 (DE3) measured for 120 secs by SPR analysisMore data for this Ligand-Target Pair
Affinity DataKd: 3.13E+3nMAssay Description:Binding affinity to human PD1 (34 to 150 residues) expressed in Escherichia coli BL21 (DE3) measured for 120 secs by SPR analysisMore data for this Ligand-Target Pair
Affinity DataKd: 1.38E+3nMAssay Description:Binding affinity to human PD1 (34 to 150 residues) expressed in Escherichia coli BL21 (DE3) measured for 120 secs by SPR analysisMore data for this Ligand-Target Pair
Affinity DataKd: 1.66E+6nMAssay Description:Binding affinity to PD1 (unknown origin) by SPR analysisMore data for this Ligand-Target Pair
Affinity DataKd: 3.30nMAssay Description:Binding affinity to human PD-1 assessed as dissociation constant by SPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.000500nMAssay Description:In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Princip...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Human)
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 2nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Human)
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 4nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:96 Well plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in PBS (W...More data for this Ligand-Target Pair
